Main distributor to Brazil and Latin America for analytical reference substances  |  Welcome! Olá! Hola! Español  |  +1.919.484.7555
You are here: Home /USFDA /The way is clear for PDUFA V but can it solve US biopharma’s R&D productivity crisis?

The way is clear for PDUFA V but can it solve US biopharma’s R&D productivity crisis?

by JMC on June 22, 2012

There is a certain irony that the one issue that is actually garnering broad bipartisan support on Capitol Hill this year – user fees – is something that involves the US Food and Drug Administration, a “regulatory agency that, frankly, has not been the focus of a lot of affection over many years from Congress and others,” said a beaming FDA Commissioner Margaret Hamburg1

Previous post:

Next post: